Clinical Trials Logo

Clinical Trial Summary

PET CT is one of the imaging tools that are used for staging of urological malignancies.

C11 Choline is a novel isotope with the advantage of its minimal secretion in the urine. This advantage makes it a potentially better metabolic marker then others such as FDG. Preliminary studies showed ~95% sensitivity in the diagnosis of TCC. Our Goal is to continue the evaluation of this method as a diagnostic and follow up tool in different urological malignancies.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00706212
Study type Observational
Source Rabin Medical Center
Contact Shay Golan, MD
Phone 972-50-744-7573
Email shaygo1@yahoo.com
Status Recruiting
Phase N/A
Start date June 2008

See also
  Status Clinical Trial Phase
Recruiting NCT04625556 - Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome